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 Introduction                          
Reports from the World Health Organization (WHO) reveal that 17.6 
million persons contracted whooping cough in 2003 resulting in 
279000 deaths; however, some authorities estimate the real figures 
of cases with pertussis to be around 50 million with 90% living in 
developing countries.1 According to the report of WHO Regional Office 
for the Eastern Mediterranean, 19000 deaths have occurred in under 
5-year-old children because of pertussis. 
464 patients were reported to have pertussis in Iran, in 2010.2 
Immunization against pertussis is included in the expanded 
program of immunization developed by the WHO and has been 
implemented in Iran since 1950. Whole cell pertussis vaccine 
is used in combination with diphtheria and tetanus toxoids (as 
DwPT) to vaccinate infants and children against these three deadly 
diseases.1 In spite of a coverage of >95% for DwPT, the incidence 
of pertussis seems to be increasing during recent years. Young 
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 Abstract                                                                                                            
Background: It seems that the incidence of pertussis-like 
illnesses is considerably increasing despite the wide coverage 
of immunization with the whole cell pertussis vaccine. We aimed 
to investigate the occurrence of pertussis in vaccinated children 
by measuring anti-pertussis antibodies. 
Methods: In this cross-sectional study, blood samples were taken 
from vaccinated children aged 2, 4, 6, 12, 18, and 72 months. 
Anti-pertussis IgG and IgA were measured by ELISA. P<0.05 
was considered significant.
Results: 725 children were enrolled in the study. Geometric mean 
titers for IgG that showed a slight decease after 2 months of 
age and increased distinctly in children aged 72 months. The 
frequency of the individuals whose IgG was above the determined 
cut-off (derived from mean+2SD) was observed in 1% of the 2, 
4, and 6-month-old infants, 6% of the 12 and 18-month-olds and 
12% of the 6-year -old children. Positive IgA titers were detected 
in 5, 9, 6, 23, 11, and 8% of children aged 2, 4, 6, 12, 18, and 72 
months, respectively.
Conclusion: Since a considerable percentage of children had 
high levels of anti-pertussis IgG antibodies (≥2 SD), positive 
anti-pertussis IgA, and most importantly an increased level of 
anti-pertussis IgG geometric mean titer at 6 years of age, further 
investigations regarding the protection provided by the presently 
used pertussis vaccine seems necessary.
Please cite this article as: Sanaei Dashti A, Karimi A, Arjmand R, Moghadami M, 
Kheirkhah T, Shiva F, Gholinejad Z, Joulaei H. Serologic Evidence of Pertussis 
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children continue to contract whooping cough 
and are placed at risk for complications and 
sometimes mortality associated with this vaccine 
preventable disease.1,3,4 Occurrence of pertussis 
in vaccinated individuals has raised questions 
about the protection afforded by the whole cell 
vaccine; numerous researchers have suggested 
different approaches for assessment of vaccine 
efficacy including estimating the prevalence of 
pertussis in vaccinated populations.1,5-8
Since pertussis may mimic other respiratory 
diseases such as adenovirus, influenza and 
mycoplasma infections, resulting in the so-called 
“pertussis-like” syndrome, relying solely on the 
clinical presentation would not be a true measure 
for documenting the disease, as many cases 
would be clinically mislabeled as pertussis. 
Current diagnostic procedures include culture, 
polymerase chain reaction (PCR), and a rise 
in antibodies through enzyme-linked immuno-
assay (ELISA).9 Isolation of Bordetella pertussis 
which is the gold standard for diagnosis is 
a difficult and time consuming procedure, 
making it impractical for epidemiologic studies.8 
Detecting the organism by PCR is rapid and 
sensitive but sensitivity decreases with time and 
with antibiotic treatment.4,8 Serology, however, 
appears to be an easily available and reliable 
technique to document definite infection with 
Bordetella pertussis; a rise in IgG antibodies 
against pertussis toxin (IgG-PT) is seen in 
>90% of individuals exposed to B. pertussis 
either through a natural infection or through 
vaccination.8-10 Serum IgA, however, does not 
rise after vaccination and is detectable only in 
children who acquire natural infection.9-11
In vaccinated children, the documentation 
of natural infection with pertussis would be 
difficult. Because of the anamnestic response 
of the immune system after immunization, a 
rapid increase in anti-pertussis antibodies is 
seen which prevents a significant difference 
in antibody concentrations between the acute 
and recovery sera. Therefore, in vaccinated 
individuals, detection of anti-pertussis IgA, single 
values of IgG antibodies above a certain level, 
and single high values of IgG antibodies 2 to 3 
standard deviations exceeding the mean value in 
vaccinated uninfected individuals have been used 
to diagnose natural infection.5,10,12
We aimed to determine the prevalence of 
pertussis in vaccinated infants and children at 
different ages ranging from 2 months to 6 years 
by measuring the anti-pertussis IgG and IgA 
antibodies. We aimed to provide an estimate of 
the protection afforded by the whole cell pertussis 
vaccine incorporated in the DwPT vaccine 
currently used in Iran for routine immunization 
of children.
 Subjects and Methods                     
This cross-sectional study was done in 6 health 
facility centers affiliated to Tehran and Shahid 
Beheshti Universities of Medical Sciences, Tehran, 
Iran. The centers were selected using cluster 
sampling. The protocol of this study was approved 
by the Ethics Committee of Shahid Beheshti 
University of Medical Sciences, Tehran, Iran.
We included disease-free and afebrile infants 
and children aged 2, 4, 6, 12, 18 and 72 months 
with a valid vaccination record (card), referring to 
centers for DwPT vaccination. The children were 
selected using the convenience sampling method. 
Children with incomplete or poorly documented 
vaccination records, those with a history of blood 
transfusion, immune-compromised children or 
those receiving immunosuppressive drugs were 
excluded from our study.
The sample size was estimated to be 100 
samples from each age group (power=80%, 
confidence interval=95%). 
Parental consent was obtained through face 
to face interview. The children’s vaccination 
cards showed that their vaccination status was 
up-to-date. After documenting the relevant data, 
2 ml venous blood was collected from each child 
and sent to the laboratory  where the sample 
was centrifuged and the serum stored at -70°C. 
Samples were then tested by ELISA for the 
presence of Anti-pertussis IgA (anti-pertussis 
toxin, anti-filamentous hemaglutinin, and anti-
lipopolysaccharides antibodies) and IgG (anti-
pertussis toxin, anti-filamentous hemaglutinin, 
and anti-lipopolysaccharides antibodies)  using 
the kit supplied by the IBL company, Germany 
(Reference No: RE56131 and RE 56141).
Serum IgG and IgA levels were measured in 
2, 4, 6, 12, 18 and 72-month-old children  before 
administering the scheduled DwPT vaccine, 
imported from the Serum Institute of India and 
is routinely administered at 2, 4, 6, 18, and 72 
months of age. The antibody levels were recorded 
at different ages and compared with baseline 
levels at 2 months.
In further analysis, the geometric mean titer 
(GMT) were classified sequentially for both IgG 
and IgA at ages 2, 4, 6, 12, and 18 months as the 
baseline levels and compared with the GMT of the 
two antibodies at higher ages. The frequency of 
seropositive subjects was also measured in all 
age groups.
A natural pertussis infection was determined 
through any of the following: 1- A positive IgA titer, 
2- To have an IgG level above the mean+2SD 
level. In each age group, after excluding IgA 
Table 1: Comparison of IgA geometric  mean±SD titers at different ages with 2, 4, 6, 12, and 18 months considered sequentially 
as bases for comparison with higher ages
Age (months) GMT(U/ml) Age (months) GMT(U/ml) P value
2 1.48±1.21 4 1.43±1.23 0.16
2 1.48±1.21 6 1.45±1.32 0.81
2 1.48±1.21 12 2.66±1.21  <0.001*
2 1.48±1.21 18 2.24±1.19 <0.001*
2 1.48±1.21 72 2.03±1.1 0.22
4 1.43±1.23 6 1.45±1.32 0.91
4 1.43±1.23 12 2.66±1.21 <0.001*
4 1.43±1.23 18 2.24±1.19 <0.001*
4 1.43±1.23 72 2.03±1.1 0.21
6 1.45±1.32 12 2.66±1.21 0.008*
6 1.45±1.32 18 2.24±1.19 0.03
6 1.45±1.32 72 2.03±1.1 0.31
12 2.66±1.21 18 2.24±1.19 0.003*
12 2.66±1.21 72 2.03±1.1 0.59
18 2.24±1.19 72 2.03±1.1 0.98
GMT: Geometric mean titer; *Statistically significant
Table 2: The estimated frequency of natural pertussis 
infection using different variables
Variable Cases/population
 IgA 64.8/1000
 IgG≥100 (6y) 104/1000
IgG>mean+2SD 91/1000
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positive individuals, as naturally infected persons 
in the remaining children, assumed as being 
uninfected, the mean+2SD level of IgG was 
assigned as the upper limit of vaccine induced 
antibody and also as a cut-off (threshold). Any 
rise above this level of IgG was assumed as a 
natural pertussis infection. 3- To have an IgG level 
≥100 IU/ml. 
Categorical variables were reported as 
frequency and percentage and for quantitative 
variables were presented as mean±standard 
deviation (SD). Antibody GMTs and related 
standard errors (SE) were calculated by 
logarithmic transformation of data. The analysis of 
antibody titers was also done using the logarithmic 
transformed data.
Linear or logistic regression analyses were 
done according to the type of dependent 
variable. To evaluate the level of antibodies 
against Burdetella pertussis between the groups, 
analysis of variance (ANOVA) and for pair wise 
comparisons Bonferroni test have been used.
To evaluate the association of categorical 
data with each other, Chi-square and Fisher’s 
exact tests were used. P<0.05 was considered 
as statistically significant. In case of performing 
multiple comparisons to evaluate a single 
hypothesis, P values were adjusted for the 
number of comparisons.
Data analysis was done assuming that all data 
are individually independent from each other. 
 Results                       
We included 725 children aged 2, 4, 6, 12, 18, and 
72 months. 380 (52%) were boys. Samples were 
collected from >100 participants in each age group. 
The most collected samples (n=182) were from the 
6-year-old group. 
Mean (±SD) IgG levels (GMTs) at 2, 4, 6, 
12, 18, and 72 months were 8.43 (±1.07), 6.31 
(±1.22), 8.29 (±1.04), 8.58 (±1.08), 7.35 (±1.11), 
14.4 (±1.06) U/ml, respectively. The mean 
(±SD) IgA levels at the same ages were 1.48 
(±1.21), 1.43 (±1.23), 1.45 (±1.32), 2.66 (±1.21), 
2.24 (±1.19), 2.03 (±1.1) U/ml, respectively 
(tables 1 and 2). 
The GMTs for IgG showed a slight fall after 
2 months and a definite rise in children aged 72 
months (figure 1).
1% of 2, 4, and 6-month-old infants, 6% of 
the 12 and 18-month-olds and 12% of 6-year-old 
children had IgG levels above the determined cut-
off (derived from mean+2SD). 1% of the 2, 4, and 
6–month-old infants, 5% of the 12 and 18–month-
olds and 10% of the 6-year-old children had IgG 
levels ≥100 IU/ml. 
GMTs of serum IgA were compared between 
different age groups, which showed significantly 
higher GMTs at certain ages (table 2). GMTs 
for IgA reached the highest levels at 12 and 18 
months of age (figure 2).
IgA levels above the assay cut-off were 
detected in 5, 9, 6, 23, 11, and 8% of the children 
at the ages of 2, 4, 6, 12, 18 and 72 months, 
respectively. Considering the equivocal results 
of IgA as well as the positive ones (IgA≥8 U/ml), 
the frequency of natural infection were 5, 9, 6, 23, 
11, and 8% at the ages of 2, 4, 6, 12, 18 and 72 
months, respectively.
Figure 1: The GMTs for IgG shows a slight fall after 2 
months and a definite rise in children aged 72 months. 
GMT: Geometric mean titer                                                                        
Figure 2: This figure shows the GMT for IgA at different ages 
of 2, 4, 6, 12, 18 and 72 months. GMTs for IgA reached the 
highest levels at 12 and 18 months of age.  GMT: Geometric 
mean titer                                                                                        
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 Discussion                       
Our findings revealed that IgG titers declined slightly 
after 2 months, and then remained constant until 
18 months of age. However, a sharp rise in the IgG 
GMT was seen at 72 months, i.e. before receiving 
the pre-school booster. The plateau in the GMT 
until 18 months can be explained by the repeated 
vaccinations including the primary series at 2, 4 and 
6 months and the first booster given between 12 and 
18 months of age. However, the unexpected sharp 
rise in IgG before the preschool booster i.e. between 
4-5 years after the previous immunization implies 
recent contact with Bordetella Pertussis, which 
could only be explained through the acquirement 
of natural infection. 
In France, 360 children were tested for 
pertussis serology 0.5 to 158 months after 
complete whole cell pertussis vaccination. 
Antibodies against pertussis antigens decreased 
rapidly after vaccination but increased secondarily 
60 months thereafter. They concluded that 
unrecognized pertussis is common in France 
despite massive and sustained immunization 
in infants and that vaccinated children become 
susceptible to infection more than 6 years after 
their last vaccination.13
Although a rise in serum IgA is observed 
only after a natural infection, all infections are 
not associated with an IgA response. Although, 
detection of IgA against Bordetella pertussis has 
a low sensitivity with a negative predictive value 
of 61%, it is highly specific for a definite diagnosis 
of pertussis with a positive predictive value of 
almost 100%.7,10 In our study serum IgA level was 
elevated in 6-12% of infants <2years of age and 
in 4% of 6-year-old children. It has been reported 
that IgA against the PT antigen rises in 20-40% 
and IgA against the anti-filamentous hemaglutinin 
is increased in 30-50% of natural infections.7,10 
In this study we measured IgA against three of 
Bordetella pertussis antigens (anti-pertussis 
toxin, anti-filamentous hemaglutinin and anti-
lipopolysaccharides antibodies). Therefore, we 
presumed that the sensitivity of IgA in our study 
would be higher than the quoted figures for the 
measurement of separate antigens. Besides, 
as the half-life of IgA antibodies is considerably 
shorter than IgG, the presence of this antibody 
denotes a recent infection. Based solely on IgA 
levels, we estimated the prevalence of natural 
infection in our studied population of vaccinated 
children at ages of 4, 6, 12, 18, and 72 months to 
be between 9-11%, with the highest percentage 
was at 18 months. In infants aged 2 months, yet 
to receive their DwPT vaccination, 5% revealed 
evidence of recent exposure to Bordetella 
pertussis. Because of the low sensitivity of IgA, 
these records are believed to be only a part of 
the real figures.
Some investigators have used cut-off points 
for single serum samples derived from the 
mean+2SDs of anti-pertussis IgG to document 
natural infection.13-17  In our study we used a similar 
strategy to estimate the frequency of the naturally 
infected vaccinated children through measuring 
anti-pertussis IgG. IgA positive children were 
excluded from each age group as naturally infected 
children. Then, a cut-off point of mean+2SD of the 
anti-pertussis IgG was assumed in the remaining 
samples (uninfected group) as the maximum 
level of vaccine induced antibody. Any rise from 
this level was considered as a natural pertussis 
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infection. However, even these figures are an 
underestimation of naturally infected individuals, 
because inclusion of IgA negative but IgG positive 
individuals in the uninfected group would increase 
the mean IgG levels. Consequently, the cut-off 
point of mean+2SD would rise, resulting in the 
underestimation of truly infected children.
Neither natural infection nor vaccination 
against pertussis provides permanent 
immunity.3,4,9 The protective effect of the DwPT 
vaccine is reported to last for a varying period 
from 4-12 years. Moreover, only about 52% 
of children would have a protective level of 
antibodies 4 years after receiving the vaccine.3,18 
In a recent study from Australia it was noticed 
that the peak rate of pertussis had shifted from 
the age of 8-9 years to 12-13 years, after the 5th 
dose of the DwPT vaccine was introduced as a 
pre-school booster in 4-5 year-old children. The 
authors concluded that the protection provided 
by the DwPT vaccine declines 6-9 years after the 
last dose.19
Immunity against pertussis, either after 
vaccination or even after natural infection does not 
bear a direct relationship with the antibody levels, 
and an individual may be protected against the 
disease even if the antibodies are undetectable in 
the blood. On the other hand, antibody levels may 
rise after an asymptomatic infection in vaccinated 
individuals.2
The WHO reports 98 proven cases of pertussis 
from Iran in 2004, and 125 cases in 2005.1 These 
figures have grossly underestimated the true 
numbers and result from under-diagnosis and 
under-reporting, both of which stem from a lack of 
definite clinical diagnostic criteria and appropriate 
laboratory methods.
Our figures vary widely from those of Ghanaie 
and colleagues from Iran who quote an incidence 
of 318/100000 in 2008 in Tehran among school 
children between the ages of 6-14 years.20 This 
disparity could be explained by the differences in 
the age of the study population in the 2 studies 
as well as the use of different criteria used for 
the diagnosis of pertussis; theirs being clinical 
manifestation plus a positive PCR.
 Conclusion                        
A considerable percentage of children had high 
levels of anti-pertussis IgG antibodies, positive 
anti-pertussis IgA, and most importantly a significant 
rise of anti-pertussis IgG GMT at 6 years of age, 
depicting a natural infection in vaccinated children. 
Further surveys need to be done to study the 
medium and long-term protection afforded by the 
current vaccine, in order to prevent the disease in 
these age group.  
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